<DOC>
	<DOCNO>NCT00673426</DOCNO>
	<brief_summary>The purpose study evaluate safety , inferiority clinical pharmacodynamic profile drug Enoxaparin Sodium produce laboratory Blausiegel compare Clexane product , produce Laboratory Sanofi-Aventis 60 patient Chronic Renal Desease .</brief_summary>
	<brief_title>Safety Evaluation Use Sodic Enoxaparin</brief_title>
	<detailed_description>Hemodialysis filter clean process endogenous exogenous metabolic blood product . The level control anticoagulants patient chronic renal disease indispensable . Evidence clot TTPa evidence activity anti-factor Xa use substrate protect patient , undergoing dialysis . The Enoxaparin sodium one act antithrombin-factor Xa inhibitor act directly inactivation antithrombin . Thus , small-chain molecule ( low molecular weight ) Enoxaparin show fundamentally anti-Xa high end low end antitrombotic . The purpose study evaluate safety , inferiority clinical pharmacodynamic profile drug Enoxaparin Sodium produce laboratory Blausiegel compare Clexane product , produce Laboratory Sanofi-Aventis 60 patient Chronic Renal Desease . The study kind parallel , randomize , double-blind systematic sampling . The drug administer 12 consecutive dialysis session dose 1 mg / kg . The activity drug verify strength marker TTPa anti-Xa security see adverse reaction evaluation function capillary . The study conduct 60 patient chronic renal desease sex , 18 year age , carry haemodialysis treatment 3 time week satisfied inclusion criterion . The investigational product randomly administer patient 12 consecutive dialysis session , dose 1 mg / kg . The primary endpoint safety use drug evaluate monitoring event : - Loss blood clot system - Blood coagulation loss capillary vein . - Thrombus capillary 3 session monitoring . - Increase patient 's hematocrit - Thrombocytopenia - Hematoma - Fever - Allergic reaction The secondary endpoint evaluation non inferiority clinic , observe criterion maintain non-coagulation extracorporeal circuit hemodialysis pharmacodynamic curve effect enoxaparin sodium verify strength marker TTPa , anti-Xa anti-IIa .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<criteria>Adults sex , regardless colour social class ; Above 18 year age , good clinical feature , medical criterion ; Patients agree participate sign Informed Consent ; Patients Chronic Kidney Disease hemodialysis treatment ( 3 time per week ) ; Patients clearance creatinine &lt; 30ml/min ; Patients detail anticoagulant hemodialysis . Not agree term describe Informed Consent ; Volunteers bearer sensitivity enoxaparin sodium ; Volunteers Patients hypersensitivity benzyl alcohol ; Volunteers history bleed disease change blood clotting could aggravate terminate clinical picture , table gastric ulcer ; Volunteers history peptic ulcer ; Patients body mass index great 30 ; Patients cancer possibility compromise function variable clotting ; Patients period postpregnancy childbirth ; Patients genetic abnormality system coagulation ; Polytraumatized patient ; Patients use glucocorticoid least 1 month ; Patients use anticoagulant ; Patients high rate bleeding ; Patients undergo surgery perform less 15 day due risk formation bruise site surgery . Hypertension 140/90 mmHg Patients use medicine could affect hemostasis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>enoxaparin</keyword>
	<keyword>chronic renal disease</keyword>
	<keyword>Anticoagulant activity enoxaparin sodic</keyword>
</DOC>